The EU butts heads with Big Pharma to make medicines cheaper

By HEOR Staff Writer

February 2, 2023

The new EU proposal to revamp its pharmaceutical regulations. The main aim is to give people a better and more affordable access to medicines.

From what I can see, there are mixed feelings about the proposal. On one hand, consumer groups and civil society organizations are applauding the EU’s efforts to make medicines more accessible. On the other hand, the pharmaceutical industry is a bit skeptical.

So, what’s in the proposal? Well, the EU is looking to shorten the period in which pharmaceutical companies can sell their medicines without competition from 10 years to just 8 years. They’re also working towards closing the gap in access to medicines among different EU member states.

It’s interesting to see how this will all play out. What are your thoughts on the EU Pharmaceutical Regulations Proposal?

Reference url

Recent Posts

Alzheimer’s Care Innovation: Advancing Implementation Across Europe

By João L. Carapinha

January 21, 2026

Pioneering Alzheimer's Care Innovation in Europe Alzheimer's care innovation is transforming Europe's approach to the disease, shifting from policy discussions to real-world implementation of disease-modifying therapies. With 10 milli...
Navigating Economic Resilience Through Life Sciences Investment

By João L. Carapinha

January 20, 2026

Navigating a Leaderless Global Economy Through Life Sciences Investment In an era of deepening geopolitical fragmentation, often termed the G-Zero world, global governments are urged to prioritize bold life sci...
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
EU Medicine Authorizations 2025: A Year of Innovation Advancements in EU Medicine Authorizations for 2025 In 2025, the European Medicines Agency (EMA) recommended 104 medicines for marketing authorisati...